GenoMed, Inc. Partners with Malaysian Company, PhenoMed Sdn Bhd, Expanding its Medical Therapeutics Services to the Asia-Pacific Markets
ST. LOUIS, Missouri & KUALA LUMPUR, Malaysia – October 24, 2003 – GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau’s Pink Sheets Symbol GMED) a St. Louis, Missouri-based medical genomics company, announced today it has partnered with the Malaysian firm, PhenoMed, in order to expand its medical therapeutics services into the Asia-Pacific region, one of the world’s largest and fastest growing healthcare markets in the world.
Dr. David W. Moskowitz, GenoMed’s CEO commented, “We are thrilled to have a Malaysian partner for a number of reasons essential to our rapid growth as a medical genomics company. From the public health point of view, PhenoMed gives us an immediate research base for conducting our clinical trial against SARS. Malaysia suffered somewhat from the SARS epidemic last spring, and is already gearing up for SARS’ recurrence this fall. It has proved difficult to acquire any SARS patients operating only from St. Louis. Second, we are excited to be able to offer our Next Generation Disease Management(tm) services for hypertension, diabetes, and emphysema to patients in Asia through PhenoMed. Third, we hope that PhenoMed will open the doors to additional highly desirable partnerships in Asia, such as with pharmaceutical companies, clinical diagnostic laboratories, physician and patient groups, national health ministries, etc. Not least exciting is the extraordinary investment in biotechnology being made by the Malaysian government and by key individuals in Malaysia, from which we hope to benefit at least indirectly.”
“There is a significant unmet need for the advanced medical services and research capabilities PhenoMed can now offer the populations in this region,” said PhenoMed’s interim Chief Operating Officer, Ezehan Reza Kamaluddin. “This partnership enables us to provide innovative health care services immediately. We are hoping to conduct clinical trials in conjunction with several Malaysian health providers next year, have scheduled discussions with physician groups as well as the Ministry of Health in support of this effort, and will immediately work toward achieving Multimedia Super Corridor status (http://www.mdc.com.my/) this year. We have a large bioinformatics research project being readied as well as several other alliances under consideration. The synergy of this partnership is nothing short of amazing, and it will prosper. Malaysia is a dynamic, resource-rich country. This exciting collaboration will be the direct beneficiary of Malaysia’s drive to assume its place on the world stage.”
About GenoMed, Inc.
GenoMed, Inc. is a Next Generation Disease Management(TM) whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) first reported that the company has applied for patents based on its finding that the ACE gene is associated with a large number of common diseases including virtually all autoimmune diseases. GenoMed is currently conducting clinical trials for SARS and West Nile virus encephalitis.
GenoMed’s research results are more fully described on its website, www.genomedics.com (click on "Company News" and then "Recent Publications").
For questions, please contact David W. Moskowitz MD, MA(Oxon.), FACP at 314-977-0110, FAX 314-977-0042, email: dwmoskowitz@genomedics.com, or visit GenoMed at www.genomedics.com.
About PhenoMed, Sdn Bhd
PhenoMed (www.phenomed.net) is a development-stage disease management and medical-pharmaceutical therapeutic company, with its primary goal being the improvement of patient outcomes through the discovery and application of "genome-aware therapeutics."™ PhenoMed is building a network of physician and health services organizations to quickly expand its medical and therapeutic service offerings throughout the Asia-Pacific region. Founded in 2003, PhenoMed is a privately held company located in Kuala Lumpur, Malaysia. For more information about the company, please visit www.phenomed.net. For questions, contact Mr. Ezehan Reza Kamaluddin, Chief Operating Officer (Interim), at ezehan@dnaphenomics.com.
Public Relations Contacts
Corporate Headquarters
Ezehan Reza Kamaluddin
Chief Operating Officer (Interim)
28-1, Level 1, Jalan 28/70A
Desa Sri Hartamas
50480 Kuala Lumpur, Malaysia
ezehan@dnaphenomics.com
. |
